key: cord-1004130-03v1q26e
authors: Qahtani, Mawath Ali; Yang, Cheng Wei Tony; Lazosky, Lynda; Li, Xuan; D’Cruz, Jonathan; Romney, Marc G; Sin, Don D
title: SARS-CoV-2 rapid antigen testing for departing passengers at Vancouver international airport
date: 2021-05-27
journal: J Travel Med
DOI: 10.1093/jtm/taab085
sha: da9c9302c5eb23746ea2a71dae2f2f6933111718
doc_id: 1004130
cord_uid: 03v1q26e

Here, we show that point-of-care rapid antigen testing for COVID-19 is feasible to implement in the departure areas of a major airports for same-day travelers and effective in ruling out possible carriers of SARS-CoV-2 in asymptomatic air travelers. This strategy may help to reduce the spread of COVID-19 via air travel.

Teaser: Here, we show that point-of-care rapid antigen testing for COVID-19 is feasible to implement in the departure areas of a major airports for same-day travelers and effective in ruling out possible carriers of SARS-CoV-2 in asymptomatic air travelers. This strategy may help to reduce the spread of COVID-19 via air travel.

Air travel is thought to be a major route of spread of severe acute respiratory coronavirus-2 (SARS-CoV-2) 1 , the virus responsible for COVID-19 (coronavirus disease-2019), across the world 2 . Accordingly, airports have instituted strict screening measures to reduce the risk of transmission on flights. Here, we describe the experience of using a point-of-care lateral flow device for COVID-19 screening in airports.

We invited passengers between the ages of 18 and 80 years, who were boarding on a same-day domestic flight on WestJet at the Vancouver International Airport (YVR) between Nov 23 rd , 2020 and Feb 28 th , 2021 to participate ( Figure S1 ). In February, we added 4 international flights, traveling from YVR to Amsterdam, the Netherlands (operated by KLM Royal Dutch Airlines). All international passengers had received polymerase chain reaction (PCR) testing for COVID-19 within 3 days prior to departure; in contrast, none of the domestic passengers had been previously tested for COVID-19. The study was approved by the University of British Columbia/Providence Research Ethics Board (#H20-03225) and registered at ClinicalTrials.gov (NCT04665193).

We collected nasopharyngeal (NP) swabs from study participants in the departure area of YVR and performed rapid antigen testing using the Panbio COVID-19 Ag Rapid Test Device (Abbott ® ) 3 according to the manufacturer's instructions. We also performed PCR on all remnant NP swab samples according to standard protocols. Continuous variables are reported as mean ±SD and categorical variables are reported as % of total.

627 travellers (405 WestJet and 187 KLM) were approached; 592 (94.4%) met the eligibility criteria and consented. All of the refusals (n=35) occurred on WestJet flights. The most common reason for refusal was the possibility of being denied boarding with a positive test (n=10; 28.6%), which was followed by the possibility of receiving a false positive result (n=6; 17.1%), fear of NP swabs (n=6; 17.1%) and a preference for PCR testing (n=5; 14.3%); 8 travelers (22.9%) did not meet the study's eligibility criteria. The demographic characteristics are summarized in Table 1 . The swab-to-testresult time was less than 20 minutes. All NP swabs tested negative on Panbio with no invalid results and were confirmed to be negative on PCR (at a cycle threshold >40). Based on a Bayesian hierarchical model with 10,000 simulations in WinBUGS software and assuming a Beta prior with an exponential hyperprior and hyperparameter 1, the median prevalence of COVID-19 in our setting was 1.2 cases per 1,000 tested individuals with a 95% credible interval of 4×10 -5 to 6×10 -3 (Figure S2) , which is consistent with a previous finding 4 .

Here, we demonstrated that COVID-19 screening using a lateral flow device is feasible in passengers departing on same day flights. All passengers tested negative both on Panbio and PCR indicating no false negatives. There were limitations to the study. Participants were volunteers and as such selection bias was possible, which may have led to an underestimation of the COVID-19 prevalence among passengers. We did not recruit children or adolescents. In conclusion, a rapid point-of-care testing strategy for COVID-19 is feasible and can be implemented on same-day flights. Although in a low prevalence setting such as same-day air-travel, antigen testing has the potential for reduced sensitivity, it may also be highly effective in ruling out passengers with COVID-19, who may be infectious 3 . Since antigen tests can also detect variants, this strategy may also be attractive in 

Importation and human-to-human transmission of a novel coronavirus in Vietnam

Risk of COVID-19 During Air Travel

Scaling up COVID-19 rapid antigen tests: promises and challenges

Effect of internationally imported cases on internal spread of COVID-19: a mathematical modelling study

The authors would also like to thank: Black Tusk Research Group, the operational team at Vancouver International airport, the WestJet staff, and the lab staff at the Centre for Heart Lung Innovation at St. Paul's Hospital for the kind support throughout the study.